Table 3.
Correlation between fibrosis burden score and clinical factors
| Factor | Categories | N | Statistics | p-value |
|---|---|---|---|---|
| Gender | Male | 37 | 0.75 [0.33, 1.00] | 0.136 |
| Female | 24 | 1.00 [0.63, 1.33] | ||
| Family history | ||||
| • CD | Yes | 6 | 1.00 [0.75, 1.50] | 0.654 |
| No | 54 | 1.00 [0.50, 1.33] | ||
| • UC | Yes | 12 | 1.00 [0.33, 1.00] | 0.228 |
| No | 48 | 1.00 [0.67, 1.33] | ||
| Smoker | Current | 1 | 1.33 [1.33, 1.33] | 0.398 |
| Ex-smoker | 0 | - | ||
| Never | 57 | 1.00 [0.50, 1.33] | ||
| Extraintestinal manifestations | ||||
| • Joint | Yes | 6 | 0.67 [0.42, 0.92] | 0.316 |
| No | 55 | 1.00 [0.50, 1.33] | ||
| • Skin | Yes | 1 | 3.00 [3.00, 3.00] | 0.115 |
| No | 60 | 1.00 [0.50, 1.33] | ||
| • Eye | Yes | 0 | - | NA |
| No | 61 | 1.00 [0.50, 1.33] | ||
| • Bone | Yes | 0 | - | NA |
| No | 61 | 1.00 [0.50, 1.33] | ||
| • Anaemia | Yes | 26 | 1.00 [0.69, 1.46] | 0.090 |
| No | 35 | 0.75 [0.50, 1.00] | ||
| • PSC | Yes | 1 | 2.00 [2.00, 2.00] | 0.160 |
| No | 60 | 1.00 [0.50, 1.33] | ||
| • None | Yes | 29 | 0.75 [0.50, 1.00] | 0.068 |
| No | 32 | 1.00 [0.67, 1.33] | ||
| Backwash ileitis | Yes | 12 | 1.00 [0.69, 1.37] | 0.634 |
| No | 48 | 1.00 [0.50, 1.33] | ||
| Extent of colitis | Extensive | 58 | 1.00 [0.50, 1.33] | 0.429 |
| Left | 3 | 0.75 [0.54, 0.88] | ||
| Proctitis | 0 | - | ||
| Medications prior to colectomy | ||||
| • Immunomodulators | Yes | 43 | 1.00 [0.67, 1.33] | 0.822 |
| No | 14 | 1.00 [0.54, 1.33] | ||
| • Anti-TNF | Yes | 37 | 1.00 [0.75, 1.67] | 0.005 |
| No | 19 | 0.67 [0.33, 1.00] | ||
| • Vedolizumab | Yes | 1 | 0.33 [0.33, 0.33] | 0.104 |
| No | 22 | 1.00 [0.69, 1.31] | ||
| Medications at time of colectomy | ||||
| • 5-ASA | Yes | 12 | 1.00 [0.67, 1.42] | 0.602 |
| No | 49 | 1.00 [0.50, 1.33] | ||
| • Systemic steroids | Yes | 52 | 1.00 [0.67, 1.33] | 0.100 |
| No | 9 | 0.50 [0.33, 0.75] | ||
| • 6MP | Yes | 6 | 0.83 [0.35, 1.00] | 0.261 |
| No | 55 | 1.00 [0.50, 1.33] | ||
| • AZA | Yes | 6 | 1.00 [0.81, 2.50] | 0.226 |
| No | 55 | 1.00 [0.50, 1.33] | ||
| • MTX | Yes | 9 | 1.00 [1.00, 1.50] | 0.166 |
| No | 52 | 1.00 [0.50, 1.33] | ||
| • Vedolizumab | Yes | 0 | - | NA |
| No | 61 | 1.00 [0.50, 1.33] | ||
| • Anti-TNF | Yes | 14 | 1.17 [0.75, 2.00] | 0.020 |
| No | 47 | 1.00 [0.50, 1.12] | ||
| • Sulphasalazine | Yes | 1 | 1.00 [1.00, 1.00] | 0.819 |
| No | 60 | 1.00 [0.50, 1.33] | ||
| • Cyclosporine | Yes | 2 | 0.88 [0.81, 0.94] | 0.951 |
| No | 59 | 1.00 [0.50, 1.33] | ||
| • Tacrolimus | No | 60 | 1.00 [0.50, 1.33] | 0.819 |
| Yes | 1 | 1.00 [1.00, 1.00] | ||
| Duration of immunomodulators | 28 | -0.15 [ -0.50, 0.24 ] | 0.45 | |
| Duration of anti-TNF | 28 | -0.28 [-0.59, 0.10] | 0.15 |
Values presented as median [25th, 75th percentile] with Kruskal–Wallis test or Spearman’s rho [95% confidence interval].
BMI, body mass index, CD, Crohn’s disease; UC, ulcerative colitis; PSC, primary sclerosing cholangitis; 5- ASA, 5-aminosalicylic acid, 6MP, mercaptopurine; AZA, azathioprine; MTX, methotrexate; TNF, tumour necrosis factor; NA, not available.